BMS enlists Meso Scale's diagnostic for Alzheimer's drug development
This article was originally published in Clinica
Executive Summary
Pharma company Bristol-Myers Squibb has signed up diagnostics specialist Meso Scale Discovery to develop a cerebrospinal fluid test for Alzheimer's disease for use in research and drug development. Financial terms of the deal were not disclosed.